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ABSTRACT
Data on the burden of disease, costs of illness, and cost-effectiveness of vaccines are needed to facilitate the
use of available anti-typhoid vaccines in developing countries. This one-year prospective surveillance was
carried out in an urban slum community in Delhi, India, to estimate the costs of illness for cases of typhoid
fever. Ninety-eight culture-positive typhoid, 31 culture-positive paratyphoid, and 94 culture-negative cases
with clinical typhoid syndrome were identified during the surveillance. Estimates of costs of illness were
based on data collected through weekly interviews conducted at home for three months following diagno-
sis. Private costs included the sum of direct medical, direct non-medical, and indirect costs. Non-patient
(public) costs included costs of outpatient visits, hospitalizations, laboratory tests, and medicines provided
free of charge to the families. The mean cost per episode of blood culture-confirmed typhoid fever was
3,597 Indian Rupees (US$ 1=INR 35.5) (SD 5,833); hospitalization increased the costs by several folds
(INR 18,131, SD 11,218, p<0.0001). The private and non-patient costs of illness were similar (INR 1,732,
SD 1,589, and INR 1,865, SD 5,154 respectively, p=0.8095). The total private and non-patient ex-ante costs,
i.e. expected annual losses for each individual, were higher for children aged 2-5 years (INR 154) than for
those aged 5-19 years (INR 32), 0-2 year(s) (INR 25), and 19-40 years (INR 2). The study highlights the
need for affordable typhoid vaccines efficacious at 2-5 years of age. Currently-available Vi vaccine is afford-
able but is unlikely to be efficacious in the first two years of life. Ways must be found to make Vi-conjugate
vaccine, which is efficacious at this age, available to children of developing-countries.
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INTRODUCTION
Typhoid fever is a common cause of morbidity in adults
and children in India and in many other developing
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countries (1). Available vaccines for typhoid fever are
not being widely used despite widespread concern
about in-vitro and clinical resistance to antibiotics (1).
Currently, no data are available on the costs associated
with typhoid fever at the community level in develop-
ing countries. Such data would facilitate cost-benefit
analyses of different preventive and curative strategies
for typhoid fever. Knowledge of costs of illness to
individuals and to the health sector by age categories 
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could also help select an appropriate vaccine for public-
health programmes among available candidates, which
differ in efficacy at different ages. 
A cohort of all 0-40-year old residents in an urban
slum community in Govindpuri, Delhi, India, was fol-
lowed from November 1995 to February 1997 to deter-
mine the incidence of typhoid fever. As reported earlier,
the incidence of blood culture-confirmed typhoid fever
among residents aged 0-40 year(s) during one calendar
year (November 1995_October 1996) was 9.7 per 1,000
and that in pre-school children was 27.3 cases per
1,000 persons at risk per year (2). This paper presents
the private and public costs of illness associated with
typhoid fever in all cases detected in the cohort, by age
and by response to antibiotic therapy. Implications for
immunization policy are discussed.
MATERIALS AND METHODS
Study population
The study area is a densely-populated urban slum of
low socioeconomic status located in Kalkaji, New
Delhi. In 1995, a census of the population of the study
area showed that 19,585 residents were living in 4,361
dwellings (Table 1).  Members of a typical household
lived in a one-room dwelling. The household members
collected water from a public or private hand-pump.
Children defaecated in open drains outside homes, and
adults walked to open areas or two public latrines out-
side the slum area. All households had electricity, and
the majority owned a television set. 
Research design and fieldwork
All households in the study area were assigned a unique
identification number. The population was divided into
clusters with 70 households in each, and 26 such clus-
ters were randomly selected for active twice-weekly
surveillance for the detection of cases with typhoid
fever (2). The remaining household clusters were kept
only under passive surveillance at health facilities and
neighbouring practitioners for the detection of fever
cases. In active surveillance areas, cases could also be
detected through passive surveillance.
Blood specimens for culture were obtained from all
children aged less than five years, identified through
either active or passive surveillance, who had fever
(temperature >38 °C). Older children and adults had to
have continuous fever for at least three days for a 
blood specimen to be obtained. These methods have
earlier been described in detail (2). Blood-collection
centres were established at the chambers of all local
medical practitioners and health facilities.
In total, 98 cases of culture-positive typhoid fever
and 31 cases of culture-positive paratyphoid were iden-
tified. Ninety-four culture-negative cases exhibiting a
syndrome of clinical symptoms of typhoid were also
treated as typhoid fever. This 'clinical typhoid' syndrome
was defined as high-grade continuous fever for seven
days or more with no other obvious cause and no response
to three days of anti-malarial therapy. A diagnosis of
'clinical typhoid' was made earlier, i.e. after five days
of fever, if the patient additionally had bradycardia or
splenomegaly. The costs of illness were estimated and are
presented separately for blood culture-positive Salmonella
enterica serotype Typhi, blood culture-positive S. enterica
serotype Paratyphi and 'clinical typhoid' cases.
Measurement and calculation of costs of illness
Data to calculate the private costs of illness were col-
lected through weekly in-person interviews conducted
in the patients' homes. In the first interview, which
took place once diagnosis was made through either
blood culture or clinical diagnosis, the enumerator
recorded treatment-seeking behaviour and expenditure
from the onset of fever. The patient (if an adult) and the
primary caregiver were interviewed to collect informa-
tion on costs of illness. Subsequently, a detailed account
of expenditure and behaviour was collected in weekly
visits continuing for 90 days after diagnosis. At weekly
interviews, the respondents reported the number of visits
made to private care providers, hospital outpatient
departments, public hospitals, local healers, and/or
pharmacies and daily expenditure on consultation fees,
laboratory tests, medicines, transportation, and other
items, including special foods and drinks for the
patient. Information on household members who
missed work due to the patient's illness was also
recorded. Only costs relating to the episode or the con-
sequences of typhoid fever were included. If a person
suffered from another illness or injury in the 90-day
period, only the expense that preceded new morbidity
was included for analysis. 
The private costs of illness included the sum of
direct medical, direct non-medical, and indirect costs.
Direct medical costs included out-of-pocket expenditure
on consultation fees, laboratory tests, and medicines. All
efforts were made to record the expenditure made by 
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the family on drugs and laboratory tests even when the
patient was admitted to a hospital. Non-medical direct
costs included out-of-pocket expenditure on trans-
portation, special foods and drinks, and other items.
Indirect costs were calculated as the product of days of
work missed by all household members and a mone-
tary value of lost productivity, proxied by the average
daily wage rate of INR 70 (US$ 1.97). [Over the course
of the study period from November 1995 to October
1996, the exchange rate between Indian rupee and the
US dollar fluctuated between INR 34.32 and 36.59 per
US$. For the costs of illness presented in this study, we
have assumed an average exchange rate, over the period,
of US$ 1=INR 35.5. All costs are expressed in 1996
Indian rupees.] The daily productivity losses of sick
children were assumed to equal one-quarter of the aver-
age daily wage between the ages of 5 and 12 years and
one-half for ages 12 to 19 years.
The non-patient costs of illness were those borne by
institutions or the public sector. The non-patient costs
were the sum of costs of outpatient visits or hospitaliza-
tion in government hospitals, laboratory tests, and medi-
cines provided free of charge to the patient. The esti-
mates of non-patient costs associated with an outpa-
tient visit (INR 200) and daily costs of hospitalization
(INR 2000) were based on calculations used in a
Masters thesis in Hospital Administration conducted at
our institute (5). These included all costs to the institu-
tion, including infrastructure, staff salaries, and other
operational costs. The estimated costs of free laboratory
tests conducted in government hospitals or provided
free of charge by the research team were based on the
lowest rates charged by the local laboratories serving
the study community.  The research team treated each
case with ciprofloxacin, the cost of which was about
INR 8 per day for pre-school children and INR 15 per
Table 1. Socioeconomic and health characteristics of the Govindpuri study area, Kalkaji, Delhi, 1995
Characteristics Findings
General   
1995 population 19,585 in 4,361 households
Average household size 4.5 persons per household
Infrastructure
Source of water Hand-pumps (public and private)_62% 
Public taps connected to municipal piped 
distribution system_27%
Private connections_11%
Sanitation Open space, public latrines, private pit-latrines
Electricity 99% 
Household socioeconomic characteristics
% of households with television 69
% of adults illiterate 36
Religion Mixed Hindu, Muslim, 
others
Predominant dwelling type 1 room, attached, one-storey 
28%_cement-floor and permanent roof
68%_either roof or floor not permanent
4%_neither roof nor floor permanent
% of households owning structure 90
% with motorcycle 2
Health indicators
Average number of episodes of diarrhoea per child per year 8
% of children aged less than 5 years who are stunted 45
% of children aged less than 5 years who are wasted 18
Estimated infant mortality 60 per 1,000
Incidence of typhoid among individuals aged 27.3 per 1,000 per year
less than 5 years 
Incidence of typhoid among individuals aged 5-18 years 11.7 per 1,000 per year
Incidence of typhoid among individuals aged >19 years 1.1 per 1,000 per year
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day for older children and adults. Twelve cases that did
not respond to ciprofloxacin within 10 days were con-
sidered as treatment failures, and most of them were
hospitalized and treated with third-generation cephalos-
porins (drug cost INR 200 per day).
Calculation of ex-ante costs of illness
The costs-of-illness calculations described above are
expost estimates as they are based on information on
direct and indirect costs incurred by the patient and
society after an individual contracted typhoid fever. It
is useful to look at the meaning of these estimates from
the perspective of a member of the study population
before he or she becomes infected, i.e. the ex-ante costs.
By multiplying the estimated costs of illness of a case
of typhoid fever by the incidence of the disease, we
obtained ex-ante costs of illness, which are an estimate
of the annual expected value of the cost of typhoid
fever to an individual in the community.  
Sensitivity analysis
A sensitivity analysis was conducted by varying three
assumptions__the assumptions on daily wages, the
non-patient costs of outpatient visits, and the daily hos-
pitalization costs. To compute conservative (i.e. low)
estimates of costs, each value was assumed to be one-
half of the base case. To compute the upper end of the
range of costs, each value was assumed to be one and
one-half times the base case. 
Statistical analysis
Data were analyzed using Stata version 7 (Stata
Corporation, College Station, TX, USA). Costs were
compared using Student's t-test assuming unequal vari-
ances if data were normally distributed and using
Wilcoxon rank sum test if the data did not fulfill para-
metric assumptions.
RESULTS
Costs of S. Typhi blood culture-positive typhoid fever
The most reliable costs-of-illness data were obtained
from culture-positive typhoid fever cases. The total
mean costs (private costs plus public/institutional
costs) of illnesses for cases detected by active surveil-
lance (INR 3,273, SD 5,646) were somewhat lower
than those detected only by passive surveillance (INR
4,287, SD 6,337, p=0.1). This may be because the
patients detected through active surveillance received 
early and optimal antibiotic treatment. The overall inci-
dence of culture-positive typhoid fever was 9.7 per
1,000 (95% CI 7.5-12.5) by active surveillance and
only 2.9 per 1,000 (95% CI 1.9-4.1) by passive surveil-
lance. Due to the relatively few typhoid cases detected
by passive surveillance, in Table 2 we have combined
the cases detected either by active surveillance or by
passive surveillance to estimate the total mean costs of
blood culture-confirmed typhoid fever (INR 3,597, SD
5,833). The costs of an episode of typhoid increased
several folds if the patient was hospitalized (p<0.0001). 
Table 3 presents the composition of the private and
non-patient (public or institutional) costs. The total pri-
vate and total non-patient costs of illness were similar
in magnitude (p=0.8). The private indirect costs
accounted for about half of the private costs of illness.
Hospitalization contributed about 70% of the average
non-patient costs. The costs of clinic visits, laboratory
tests, and medicines were all relatively small. 
Table 4 shows the private and non-patient (public or
institutional) costs by age for culture-confirmed typhoid
fever. The age cohorts of 2-5, 5-19, and >19 years had
comparable mean costs of illness. However, the com-
position of the costs was quite different for the three
age cohorts. The private costs were much higher for
adults than for children aged 2-5 years (p<0.05) and
5-19 years (p=0.06), largely because of their high indi-
rect costs from loss of work. The non-patient costs for
adult patients were low because they were rarely hos-
pitalized. Pre-school children with typhoid fever were
more often hospitalized, resulting in a much higher cost
to the public sector.  
High costs in many typhoid episodes were due to
slow response to treatment, i.e. continued fever after
10 days of ciprofloxacin treatment requiring hospitali-
zation and intravenous third-generation cephalosporins.
The mean total costs for clinically slow responders
were INR 10,739 (SD 11,604) compared to INR 2,867
(SD 13,030) for early responders (p<0.05). 
The annual ex-ante private expected losses to an
individual in the study area were quite small (INR 18;
Table 5). The calculations are based on the population-
based incidence and costs of blood culture-confirmed
typhoid fever cases detected through active surveil-
lance. These ex-ante private costs were the highest for
pre-school children aged 2-5 years  (INR 37), followed
by school-age children (INR 21). However, if one looks
at the expected annual losses from the perspective of
both individual and society (private plus non-patient
costs), the ex-ante costs of illness for pre-school chil-
dren (INR 154) were much larger. This is because the
total costs for cases among pre-school children were com-
parable with the costs of illness of the older children and 
Typhoid fever in Indian urban slum community 308
Table 2. Mean (SD) duration of fever, hospitalization rate, and mean total costs of illness by diagnosis (1996 INR)
Blood culture-confirmed      Blood culture-confirmed    'Clinical typhoid'*
Feature        typhoid (n=98)                  paratyphoid (n=31)                 (n=94)    
Total duration (days) of fever 14.2 (8.7) 10.4 (5.4) 15.6 (7.5)
% of cases hospitalized 11.1 3.1 14.8
Mean total cost 3,597 (5,833) 1,785 (1,331) 4,547 (7,890)
Mean total cost if hospitalized 18,131 (11,218) _† 24,201 (11,923)
Mean total cost if not hospitalized 2,111 (1,375) 1,785 (1,331) 2,336 (2,449)
*This category includes patients who had clinical features of typhoid but were blood culture-negative
†Only 1 of 31 cases hospitalized
Table 3. Mean (SD) costs-of-illness components by components of private and non-patient costs (1996 INR)
Cost-of-illness                    Blood culture-confirmed       Blood culture-confirmed             'Clinical typhoid'*
component typhoid (n=98)                   paratyphoid (n=31)                          (n=94) 
Private costs 
Medical direct 277 (459) 174 (225) 432 (785)
Non-medical direct 648 (725) 423  (489) 528 (661)
Indirect 806 (925) 795 (897) 1,134 (1,521)
Total private costs 1,732 (1,589) 1,393 (1,246) 2,072 (2,420)
Non-patient costs
Clinic visits 269 (394) 116 (192) 328 (506)
Hospitalizations 1,316 (4,903) 0 (0) 1,883 (6,467)
Laboratory tests 157 (31) 161 (44) 157 (27)
Medicines 125 (86) 126 (90) 118 (163)
Total non-patient costs 1,865 (5,154) 391 (217) 2,475 (6,836)
*This category includes patients who had clinical features of typhoid but were blood culture-negative
Table 4. Mean (SD) costs of illness and hospitalization rate by age for blood culture-positive typhoid fever (1996 INR)
Age (years) cohort Private cost                   Non-patient Total cost    Percentage of casesof illness                    cost of illness                  of illness              hospitalized
0-2 (n=3) 1,144 (300) 663 (530) 1,807 (672) 0.0
2-5 (n=33) 1,191 (1,230) 2,764 (6,317) 3,955 (7,101) 21.4
5-19 (n=51) 1,894 (1,733) 1,622 (4,933) 3,516 (5,691) 8.6
19 and above (n=9) 2,999 (1,462) 318 (210) 3,317 (1,489) 5.3
Table 5. Overall and age-specific (1996 INR) ex-ante costs of illness using incidence estimates and mean costs
from cases identified through active surveillance
Age (years) Including blood culture-positive Including both blood culture-positive
cohort 
typhoid cases only                                        and 'clinical typhoid' cases
Private cost     Non-patient cost     Total cost Private cost     Non-patient cost     Total cost   
0-2 16 9 25 28 16 44
2-5 37 118 154 56 179 235
5-19 21 11 32 35 17 53
19 and above 2 0 2 11 1 12
All ages 15 17 32 26 31 57
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adults but the incidence of typhoid fever among pre-
school children was much higher. Also, the majority of
the costs for the 2-5-year cohort were non-patient costs
due to their higher hospitalization rates.
Costs of blood culture-positive paratyphoid fever
The average ex-post cost of illness of a paratyphoid case
was about half that of blood culture-confirmed typhoid
cases (p=0.06; Table 2). This was expected because
none of the paratyphoid patients was hospitalized due to
the milder nature of the disease (6). The total private
costs of illness were only marginally lower for blood
culture-positive paratyphoid cases than for blood culture-
confirmed typhoid patients (p=0.3; Table 3). 
Costs of blood culture-negative 'clinical typhoid fever'
Diagnosis of typhoid by blood culture is highly specific
but the sensitivity is only 40-45% when compared with
a combination of bone-marrow aspirate, blood, and stool
culture (7-9). The incidence of blood culture-confirmed
typhoid fever is, thus, a significant under-estimate of
the true incidence of typhoid fever. Cost data for culture-
negative 'clinical typhoid' are presented separately in
Tables 2 and 3.
The mean total costs of illnesses of 'clinical typhoid'
cases were somewhat higher than that of blood culture-
positive typhoid  fever cases, but this difference was
not significant (p=0.9; Table 2). The relative sizes of
the cost components were comparable between these
two types of cases (Table 3).
The ex-ante costs of illness increased substantially if
both culture-positive and clinical typhoid cases were con-
sidered as true cases of typhoid fever (private costs INR
45 and total costs to society INR 92) rather than blood
culture-positive cases only (private costs INR 18 and total
costs to society INR 37). This increase in the ex-ante costs
of illness was proportionately much greater for adults
than for younger persons. Before this adjustment for clini-
cal typhoid cases, the ex-ante costs of illness for an adult
was INR 5 versus INR 30 after this adjustment.
Sensitivity analysis
The total mean costs of illness were INR 2,398 using
the most conservative assumption about costs and INR
4,792 using the least conservative assumption com-
pared to the base case mean of INR 3,597. Similarly,
the ex-ante costs for culture-proven typhoid fever varied
from INR 24 to INR 74 compared to the base case value
of INR 37, and those based on an incidence estimate
that included both culture-proven typhoid and 'clinical
typhoid' varied from INR 60 to INR 124 compared to
the base case value of INR 92.
The ex-ante costs of illness, shown in Table 5, might
be considered to be lower-end estimates because they
are based on costs from cases identified through active
surveillance. We, therefore, estimated the upper-end ex-
ante costs of illness by multiplying the incidence of
typhoid fever obtained through active surveillance by
the costs from cases identified through passive surveil-
lance. This analysis showed that the ex-ante costs for
culture-proven typhoid were INR 43 (sensitivity analysis
range  28-58) and those for both culture-proven typhoid
and 'clinical typhoid' were INR 77 (range 50-103). The
highest ex-ante costs were for the 2-5-year age cohort:
INR 200 (range 124-276) for culture-proven typhoid and
INR 305 (range 189-420) for both culture-proven
typhoid and 'clinical typhoid'. 
DISCUSSION
The main findings of this study are that there were subs-
tantial costs associated with an episode of typhoid fever
and that the private costs of illness were comparable
with non-patient costs even in a low-income study popu-
lation where most medical services are provided either
free of charge or at heavily subsidized prices. Further,
the costs were several-fold higher for those who needed
hospitalization or who did not respond adequately to
antibiotic therapy. Finally, our analysis demonstrated
that the costs of illness in pre-school children were as
high as those in older children and adults.
The costs of illness shown in this paper are based on
direct measurement of reported expenses and on some
assumptions regarding daily wages, hospitalizations,
and outpatient visit costs; sensitivity analysis indicated
that these costs could vary by +33% from the mean
estimates presented in this paper. The findings of the
present study indicate that as clinical or in-vitro antibio-
tic resistance increases, the costs of illness are likely to
increase substantially because of increased hospitaliza-
tions. Strategies to prevent the development of antibio-
tic resistance, therefore, deserve a high priority from
an economic and humanitarian perspective. In high-
incidence areas, physicians tend to treat empirically
with anti-typhoid agents, usually fluoroquinolones. The
use of vaccines could reduce the probability of such an
illness being typhoid fever, restrict antibiotic use, and
thereby limit the development of antibiotic resistance.
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The ex-ante costs of illness were the highest for pre-
school children. The currently-marketed Vi and Ty21a
vaccines have been tested for efficacy only in school-
age children and adults, although it would seem likely,
at least for Vi vaccine, that efficacy extends down to
two years of age. Given the high ex-ante costs of ill-
ness in pre-school children aged 2-5 years, in whom
the Vi vaccine is theoretically applicable, data that
demonstrate the efficacy of Vi vaccine at this age are
urgently required. Newer vaccines, such as Vi-conju-
gate, may be capable of protecting infants, but their
affordability in developing countries is uncertain. 
An important issue in ex-ante cost calculations and
in subsequent cost-benefit calculations is the low sen-
sitivity of blood culture for diagnosis of typhoid fever
(7-9). Because the average duration of fever and hos-
pitalization for 'clinical typhoid' was similar to culture-
positive cases and was much greater than those expected
in acute febrile viral illnesses, a high proportion of the
'clinical typhoid' cases in this study may have been
true typhoid cases.
Our calculated costs of illness as a measure of bene-
fits of reduction in the incidence of a disease have limi-
tations as these did not include the costs relating to
pain and suffering incurred by the patient, the costs
associated with the small mortality risk from typhoid,
and behavioural changes that households may make to
avoid contracting the disease, such as boiling water.
There are also the opportunity costs of a typhoid patient
taking a hospital bed from a potentially more severely-
ill patient. These costs-of-illness estimates are, thus,
conservative. However, the willingness to pay for the
vaccine depends on the individual's perception of risk.
A slum dweller, for instance, may be willing to pay
very little to avoid typhoid fever, but might be willing
to pay a considerable sum if he or a member of his
family gets typhoid fever. Information on willingness
to pay for the vaccine was not collected in this study.
We believe that these are the first estimates of costs
of illness due to typhoid fever in a specific community
in India and among the most detailed estimates available
for any developing country. These estimates should
facilitate cost-benefit analyses of various preventive
strategies, including mass and selective immunizations.
The high disease burden and several-fold higher non-
patient costs of typhoid fever in pre-school children
compared to older children and adults imply that greater
attention should be given to the development and use of
vaccines that are efficacious in pre-school children. 
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